TrialThe journal of headache and pain2022

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.

Peter McAllister et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.